1. Home
  2. Detail

@riskafebr9: Membalas @Finaanggara752 #skintific

Riskafebr9
Riskafebr9
Open In TikTok:
Region: ID
Saturday 26 September 2026 02:09:59 GMT
1252
7
0
0

Music

Download

No Watermark .mp4 (6.77MB) No Watermark(HD) .mp4 (6.82MB) Watermark .mp4 (0MB) Music .mp3

Comments

There are no more comments for this video.
To see more videos from user @riskafebr9, please go to the Tikwm homepage.

Other Videos

#jay ver. 3/6 #enhypen #parkjongseong #fypkpop #xyzbca
#jay ver. 3/6 #enhypen #parkjongseong #fypkpop #xyzbca
#learnontiktok #satisfying #floptok 💔
#learnontiktok #satisfying #floptok 💔
من ارشيف تاريخ الثراث الشعبي المغربي و خاصة في فترة الباشا التهامي الكلاوي الذي معروفاً بحبه الأسطوري لمظاهر البذخ، والترف، وإقامة الحفلات الكبرى في قصوره بمراكش وفاس وتلوات. في هذا السياق، أصبحت
من ارشيف تاريخ الثراث الشعبي المغربي و خاصة في فترة الباشا التهامي الكلاوي الذي معروفاً بحبه الأسطوري لمظاهر البذخ، والترف، وإقامة الحفلات الكبرى في قصوره بمراكش وفاس وتلوات. في هذا السياق، أصبحت "العيطة الحوزية" (خاصة عيطة الساكن والمخزنية) حاضرة بقوة في مجالس الباشا. #نوستالجيا #مغرب #زمن_الطيبين #ذكريات مدينة #مراكش
Three recent obesity studies caught my attention for three very different reasons: One looked at a rare vision complication reported with GLP-1 medications. One asked whether semaglutide’s cardiovascular benefits differed in people who were already frail. And one followed people with obesity and prediabetes for three years to see what happened to both weight and progression to type 2 diabetes. What I like about putting these studies together is that they show how much bigger obesity medicine is than “how much weight did someone lose?” We’re studying long-term health outcomes, uncommon safety signals, different patient populations, and whether treatment can change the trajectory of obesity-related disease. And, as always, the details matter: an observational association is not the same thing as causation, a post-hoc analysis has limitations, and results from a specific clinical-trial population shouldn’t automatically be generalized to everyone. This is what I mean when I say obesity medicine is about a lot more than the number on the scale. #ObesityMedicine #ObesityResearch #GLP1 #Semaglutide #Tirzepatide
Three recent obesity studies caught my attention for three very different reasons: One looked at a rare vision complication reported with GLP-1 medications. One asked whether semaglutide’s cardiovascular benefits differed in people who were already frail. And one followed people with obesity and prediabetes for three years to see what happened to both weight and progression to type 2 diabetes. What I like about putting these studies together is that they show how much bigger obesity medicine is than “how much weight did someone lose?” We’re studying long-term health outcomes, uncommon safety signals, different patient populations, and whether treatment can change the trajectory of obesity-related disease. And, as always, the details matter: an observational association is not the same thing as causation, a post-hoc analysis has limitations, and results from a specific clinical-trial population shouldn’t automatically be generalized to everyone. This is what I mean when I say obesity medicine is about a lot more than the number on the scale. #ObesityMedicine #ObesityResearch #GLP1 #Semaglutide #Tirzepatide
#foryou #nyc #fyp #waterballoons #prank
#foryou #nyc #fyp #waterballoons #prank
Benim hayallerin uçukluk 🥲
Benim hayallerin uçukluk 🥲

About

Legal